Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
This study has been completed.
Study NCT00001683   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: March 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Melanoma
Neoplasm Metastasis
Renal Cell Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Renal Cell
Neoplasms
More general conditions related to this trial
Adenocarcinoma
Immune System Diseases
Immunoproliferative Disorders
Kidney Diseases
Kidney Neoplasms
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplastic Processes
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pathologic Processes
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
COL-3
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services